# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k133002   
B. Purpose for Submission: New device   
C. Measurand: Total beta human chorionic gonadotropin $\beta$ -hCG) in venous whole blood and plasma   
D. Type of Test: Quantitative enzyme-linked immunoassay   
E. Applicant: Abbott Point of Care, Inc.

# F. Proprietary and Established Names:

i-STAT® Total Beta-Human Chorionic Gonadotropin ( $\beta$ -hCG) Test i-STAT® Total $\beta$ -hCG Controls i-STAT® Total $\beta$ -hCG Calibration Verification Materials

# G. Regulatory Information:

1. Regulation section: 21 CFR 862.1155, Human chorionic gonadotropin test system 21 CFR 862.1660, Quality Control Material (assayed and unassayed)

2. Classification: Class II – Test System Class I, Reserved – Quality Control material

3. Product code: DHA – Test system JJX – Control material

4. Panel: Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): See Indications for Use below.

2. Indication(s) for use:

The i-STAT® Total Beta human Chorionic Gonadotropin $( { \beta } { \cdot } { \mathrm { h C G } } )$ test is an in vitro diagnostic test for the quantitative and qualitative determination of $\beta$ -hCG in venous whole blood or plasma samples using i-STAT 1 Analyzer Systems. The test is intended to be used as an aid in the early detection of pregnancy and is for prescription use only.

The i-STAT® Total $\beta$ -hCG Controls are used to monitor performance of the i-STAT Total $\beta$ -hCG test.

The i-STAT® Total $\beta$ -hCG Calibration Verification materials are used to verify the calibration of the i-STAT Total $\beta$ -hCG test throughout the reportable range.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: i-STAT 1 analyzers (models 300 and 300W)

# I. Device Description:

Each i-STAT Total $\beta$ -hCG assay cartridge includes a sample inlet, sensors to detect the total $\beta$ -hCG (see test principle below), and the necessary reagents needed to perform the test (shown in the table below). The i-STAT Total $\beta$ -hCG Controls and Calibration Verification Materials are designed for use with the assay system. The cartridge contains a buffer and preservatives.

<table><tr><td rowspan=1 colspan=1>Component</td><td rowspan=1 colspan=1>Biological Source</td></tr><tr><td rowspan=1 colspan=1>Anti - hCG Antibody/Alkaline Phosphatase Conjugate</td><td rowspan=1 colspan=1>Murine IgG : Bovine Intestine</td></tr><tr><td rowspan=1 colspan=1>IgG</td><td rowspan=1 colspan=1>Murine IgG</td></tr><tr><td rowspan=1 colspan=1>IgM</td><td rowspan=1 colspan=1>Murine IgM</td></tr><tr><td rowspan=1 colspan=1>Sodium Aminophenyl Phosphate</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>Porcine Intestine</td></tr></table>

# J. Substantial Equivalence Information:

1. Predicate device name(s):

Abbott ARCHITECT® Total $\beta$ -hCG assay   
Cliniqa Beta HCG Control Level 1, 2, 3   
Cliniqa Beta HCG Calibration Verification Control Level 1, 2, 3

2. Predicate 510(k) number(s):

k983424   
k121237

3. Comparison with predicate:

<table><tr><td colspan="1" rowspan="1">Characteristics</td><td colspan="1" rowspan="1">APOC i-STAT Total β-hCG test(Candidate k133002)</td><td colspan="1" rowspan="1">Abbott ARCHITECT Totalβ-hCG assay(Predicate k983424)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The i-STAT® Total Beta humanChorionic Gonadotropin (β-hCG)test is an in vitro diagnostic test forthe quantitative and qualitativedetermination of β-hCG in venouswhole blood or plasma samplesusing i-STAT 1 Analyzer Systems.The test is intended to be used as anaid in the early detection ofpregnancy and is for prescriptionuse only.</td><td colspan="1" rowspan="1">Same except intended forserum and plasma samples</td></tr><tr><td colspan="1" rowspan="1">Assay Methodology</td><td colspan="1" rowspan="1">Two site ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Enzyme Detection</td><td colspan="1" rowspan="1">Electrochemical</td><td colspan="1" rowspan="1">ChemiluminescentMicroparticle Immunoassay</td></tr><tr><td colspan="1" rowspan="1">Reportable Range</td><td colspan="1" rowspan="1">5.0-2000 IU/L undiluted</td><td colspan="1" rowspan="1">1.2-15,000 IU/L undiluted</td></tr><tr><td colspan="1" rowspan="1">Samples</td><td colspan="1" rowspan="1">Sodium and Lithium Heparin wholeblood and Sodium and LithiumHeparin plasma</td><td colspan="1" rowspan="1">Serum and Heparin or EDTAPlasma</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">i-STAT Total β-hCG Controlsand i-STAT Total β-hCGCalibration Verification Material(Candidate k133002)</td><td colspan="1" rowspan="1">Cliniqa Beta HCG ControlLevel 1, 2, 3 and Cliniqa BetaHCG CalibrationVerification Control Level 1,2, 3 (Predicate k121237)</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">The i-STAT® Total β-hCG Controlsare used to monitor performance ofthe i-STAT Total β-hCG test.The i-STAT® Total β-hCGCalibration Verification Materialsare used to verify the calibration ofthe i-STAT Total β-hCG testthroughout the reportable range.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Human serum with added bufferstabilizers, and purified humanhormones</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">WHO 5th International ReferenceStandard, 07/364</td><td colspan="1" rowspan="1">WHO 4th InternationalReference Standard, 75/589</td></tr><tr><td colspan="1" rowspan="1">Form</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Open Vial Stability</td><td colspan="1" rowspan="1">30 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Values</td><td colspan="1" rowspan="1">Specific for each lot</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="1" rowspan="1">Opened: 30 days at 2-8 °CShelf Life: 3 years at 2-8 °C</td><td colspan="1" rowspan="1">Same</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

· CLSI EP05-A2: Evaluation of Precision Performance of Quantitative Measurement Methods CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures   
· CLSI EP07-A2: Interference Testing in Clinical Chemistry   
· CLSI EP09-A2: Method Comparison and Bias Estimation Using Patient Samples   
· CLSI EP12-A2: User Protocol for Evaluation of Qualitative Test Performance CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures   
CLSI C28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory   
· CLSI I/LA30-A: Immunoassay Interference by Endogenous Antibodies

# L. Test Principle:

The i-STAT Total $\beta$ -hCG assay test cartridge uses a two-site enzyme-linked immunosorbant assay (ELISA) method. Antibodies specific for hCG are located on an electrochemical sensor fabricated on a silicon chip. Also deposited in another location on the sensor silicon chip is an antibody/alkaline phosphatase enzyme conjugate specific to a separate portion of the human chorionic gonadotropin molecule. The whole blood or plasma sample is brought into contact with the sensors allowing the enzyme conjugate to dissolve into the sample. The hCG within the sample becomes labeled with alkaline phosphatase and is captured onto the surface of the electrochemical sensor during an incubation period of approximately seven minutes. The sample, as well as excess enzyme conjugate, is washed off the sensors. Within the wash fluid is a substrate for the alkaline phosphatase enzyme. The enzyme bound to the antibody/antigen/antibody sandwich cleaves the substrate, releasing an electrochemically detectable product. The electrochemical (amperometric) sensor measures this enzyme product, which is proportional to the concentration of hCG within the sample. The default setting on the handheld is a display of the quantitative hCG value as well as a qualitative interpretation of the hCG test result. The handheld can be customized to disable or enable the qualitative hCG interpretation.

# M. Performance Characteristics (if/when applicable):

# 1. Analytical performance:

# a. Precision/Reproducibility:

Two separate precision studies were performed at the point of care (POC). In the first study using spiked lithium heparinized whole blood, all target concentrations were evaluated at the same three POC sites. In the second study for lithium heparinized plasma samples, the $5 \ \mathrm { I U / L }$ target concentration was evaluated at 3 different POC sites compared to the other evaluated plasma concentrations. Analyses were based on CLSI EP5-A2.

For plasma samples, precision studies were conducted over 5 days on five analyzers, yielding 25 replicates per sample/level across 3 sites for each concentration level (total $\Nu { = } 7 5$ per sample concentration level). Results are shown in the Table below:

Reproducibility at 3 POC sites for plasma samples:   

<table><tr><td rowspan=2 colspan=1>TargetConcentration</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(IU/L)</td><td rowspan=1 colspan=2>Within-Day</td><td rowspan=1 colspan=2>Within-Site</td><td rowspan=1 colspan=2>Overall</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>5 IU/L</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>13.61</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>16.05</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>18.7</td></tr><tr><td rowspan=1 colspan=1>25 IU/L</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>24.3</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>5.16</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>5.16</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>5.18</td></tr><tr><td rowspan=1 colspan=1>1150 IU/L</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>1155.7</td><td rowspan=1 colspan=1>49.76</td><td rowspan=1 colspan=1>4.31</td><td rowspan=1 colspan=1>50.77</td><td rowspan=1 colspan=1>4.39</td><td rowspan=1 colspan=1>53.08</td><td rowspan=1 colspan=1>4.59</td></tr><tr><td rowspan=1 colspan=1>1875 IU/L</td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>1874.5</td><td rowspan=1 colspan=1>104.95</td><td rowspan=1 colspan=1>5.60</td><td rowspan=1 colspan=1>104.95</td><td rowspan=1 colspan=1>5.60</td><td rowspan=1 colspan=1>111.11</td><td rowspan=1 colspan=1>5.93</td></tr></table>

For whole blood sample evaluations, at each POC site, 21 replicates were tested for each whole blood sample. The 21 replicates included 3 replicates for each of 7 analyzers at each POC site. Results are shown below:

Reproducibility for whole blood samples:   

<table><tr><td colspan="1" rowspan="2">TargetConcentration</td><td colspan="3" rowspan="1">POC site #1, N=21</td><td colspan="3" rowspan="1">POC site #2, N=21</td><td colspan="3" rowspan="1">POC site #3, N=21</td></tr><tr><td colspan="1" rowspan="1">mean</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">mean</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">mean</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">5 IU/L</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">0.81</td><td colspan="1" rowspan="1">15.45</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">0.39</td><td colspan="1" rowspan="1">7.71</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">0.42</td><td colspan="1" rowspan="1">8.51</td></tr><tr><td colspan="1" rowspan="1">25 IU/L</td><td colspan="1" rowspan="1">24.8</td><td colspan="1" rowspan="1">1.44</td><td colspan="1" rowspan="1">5.80</td><td colspan="1" rowspan="1">30.5</td><td colspan="1" rowspan="1">1.87</td><td colspan="1" rowspan="1">6.14</td><td colspan="1" rowspan="1">27.9</td><td colspan="1" rowspan="1">1.97</td><td colspan="1" rowspan="1">7.04</td></tr><tr><td colspan="1" rowspan="1">800-1000 IU/L</td><td colspan="1" rowspan="1">935.5</td><td colspan="1" rowspan="1">60.69</td><td colspan="1" rowspan="1">6.49</td><td colspan="1" rowspan="1">1008.1</td><td colspan="1" rowspan="1">55.65</td><td colspan="1" rowspan="1">5.52</td><td colspan="1" rowspan="1">842.5</td><td colspan="1" rowspan="1">50.55</td><td colspan="1" rowspan="1">6.00</td></tr><tr><td colspan="1" rowspan="1">1600-2000 IU/L</td><td colspan="1" rowspan="1">2039.8</td><td colspan="1" rowspan="1">111.61</td><td colspan="1" rowspan="1">5.47</td><td colspan="1" rowspan="1">1641.0</td><td colspan="1" rowspan="1">105.81</td><td colspan="1" rowspan="1">6.45</td><td colspan="1" rowspan="1">1816.4</td><td colspan="1" rowspan="1">132.52</td><td colspan="1" rowspan="1">7.30</td></tr></table>

All blood or plasma sample results with a measured hCG concentration $< 5 \mathrm { I U } / \mathrm { L }$ will be reported as $^ { < < } 5 \mathrm { ~ I U / L ~ } ^ { \prime \prime }$ by the test system.

# b. Linearity/assay reportable range:

# Linearity study:

A study was performed to demonstrate that the i-STAT Total $\beta$ -hCG assay is linear across the claimed measuring interval of $5 . 0 \ : \mathrm { I U / L }$ to $2 0 0 0 . 0 \mathrm { I U / L }$ . Lithium heparinized whole blood and plasma samples from 6 donors were spiked with a primary spiking solution prepared from WHO $5 ^ { \mathrm { t h } }$ IS (07/364). Nine hCG levels/samples with concentrations well-distributed across the range (from $4 . 9 \ : \mathrm { I U / L }$ to ${ > } 2 0 0 0 \ \mathrm { I U / L }$ ) were prepared by admixing according to recommendations in CLSI EP06-A. Replicate samples $( \mathrm { N } { \geq } 1 0 )$ were tested on multiple i-STAT 1 Analyzers.

Analyses demonstrated linearity across the claimed measuring interval of $5 . 0 \ : \mathrm { I U / L }$ to $2 0 0 0 . 0 \mathrm { I U / L }$ . The linear regression analysis results are:

Whole blood: $\mathrm { y } { = } 1 . 0 4 \mathrm { x } { + } 0 . 6 9$ , $\mathrm { r } { = } 0 . 9 9 0 1$ Plasma: y=0.92x-0.35, $\mathrm { r } { = } 0 . 9 9 2 9$

# Recovery study

A dilution recovery study was performed using lithium heparinized whole blood and plasma samples from six donors. Each donor sample was then mixed with a primary spiking solution prepared from WHO $5 ^ { \mathrm { t h } }$ IS (07/364) to prepare 9 levels of samples, which were then tested on at least ten assay cartridges. Percent recovery or absolute bias was calculated at each level as shown below:

<table><tr><td rowspan=2 colspan=1>Level</td><td rowspan=1 colspan=3>Whole Blood</td><td rowspan=1 colspan=3>Plasma</td></tr><tr><td rowspan=1 colspan=1>Mean(expected)</td><td rowspan=1 colspan=1>Mean(observed)</td><td rowspan=1 colspan=1>%recoveryor absolutebias</td><td rowspan=1 colspan=1>Mean(expected)</td><td rowspan=1 colspan=1>Mean(observed)</td><td rowspan=1 colspan=1>%recoveryor absolutebias</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1936.4</td><td rowspan=1 colspan=1>1974.6</td><td rowspan=1 colspan=1>102.0 %</td><td rowspan=1 colspan=1>1972.6</td><td rowspan=1 colspan=1>1811.5</td><td rowspan=1 colspan=1>91.8 %</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>972.7</td><td rowspan=1 colspan=1>989.3</td><td rowspan=1 colspan=1>101.7 %</td><td rowspan=1 colspan=1>986.5</td><td rowspan=1 colspan=1>895.5</td><td rowspan=1 colspan=1>90.8 %</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>644.8</td><td rowspan=1 colspan=1>677.4</td><td rowspan=1 colspan=1>105.1 %</td><td rowspan=1 colspan=1>657.5</td><td rowspan=1 colspan=1>622.1</td><td rowspan=1 colspan=1>94.6 %</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>484.2</td><td rowspan=1 colspan=1>509.5</td><td rowspan=1 colspan=1>105.2 %</td><td rowspan=1 colspan=1>493.3</td><td rowspan=1 colspan=1>475.0</td><td rowspan=1 colspan=1>96.3 %</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>242.2</td><td rowspan=1 colspan=1>261.4</td><td rowspan=1 colspan=1>107.9 %</td><td rowspan=1 colspan=1>246.9</td><td rowspan=1 colspan=1>234.1</td><td rowspan=1 colspan=1>94.8 %</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>121.3</td><td rowspan=1 colspan=1>128.2</td><td rowspan=1 colspan=1>105.7 %</td><td rowspan=1 colspan=1>123.5</td><td rowspan=1 colspan=1>109.2</td><td rowspan=1 colspan=1>88.4 %</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>60.6</td><td rowspan=1 colspan=1>62.9</td><td rowspan=1 colspan=1>103.8 %</td><td rowspan=1 colspan=1>61.8</td><td rowspan=1 colspan=1>54.5</td><td rowspan=1 colspan=1>88.2 %</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>24.3</td><td rowspan=1 colspan=1>26.6</td><td rowspan=1 colspan=1>109.5 %</td><td rowspan=1 colspan=1>24.8</td><td rowspan=1 colspan=1>22.6</td><td rowspan=1 colspan=1>91.0 %</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>0.7 IU/L</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.8 IU/L</td></tr></table>

For whole blood samples with hCG concentrations ${ > } 5 \mathrm { I U } / \mathrm { L }$ , the individual $\%$ recovery ranged from $9 1 . 1 \%$ to $1 1 8 . 5 \%$ , and for plasma samples from $8 1 . 8 \%$ to $1 0 3 . 3 \%$ when compared to WHO hCG $5 ^ { \mathrm { t h } }$ IS. For whole blood samples with hCG at a concentration of ${ \sim } 5 \ \mathrm { I U / L }$ , the individual bias ranged from 0.3 to $1 . 1 \ : \mathrm { I U / L }$ , and for plasma samples from -0.2 to $- 1 . 2 \ : \mathrm { I U / L }$ , when compared to WHO hCG $5 ^ { \mathrm { t h } }$ IS.

The sponsor has a limitation in their labeling that states   
“End-users may obtain individual results with ${ > } 1 5 \%$ negative bias for plasma samples when hCG concentrations are $> 5 \ \mathrm { I U } / \mathrm { L } ^ { \ ' }$ .

# Hook effect evaluation:

The assay was evaluated for high dose hook effect in lithium heparinized plasma and whole blood samples. Samples were spiked to high levels of hCG using commercially available hCG. Each sample was diluted into the measuring interval of the i-STAT Total $\beta$ -hCG assay and results were multiplied by the dilution factor in order to assign the actual concentration of the sample being tested. Seven samples with hCG levels ranging from 100,000 to ${ > } 6 0 0 { , } 0 0 0 \ \mathrm { I U / L }$ were evaluated.

The Sponsor defines a sample unaffected by hook as a sample that produced a signal greater than the signal produced by a sample at $2 0 0 0 \mathrm { I U / L }$ (such that the i-STAT Analyzer would indicate a result of $^ { \mathrm { c c } } { > } 2 0 0 0 . 0 \mathrm { I U / L } ^ { \mathrm { 3 } }$ ). Plasma samples with hCG concentrations up to $4 5 0 { , } 0 0 0 \ \mathrm { I U / L }$ showed no hook effect. Whole blood samples with hCG concentrations up to $6 5 0 { , } 0 0 0 \mathrm { I U / L }$ showed no hook effect.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability:

The measurands in the Controls and Calibration Verification Materials are traceable to the WHO $5 ^ { \mathrm { t h } }$ International Standard (NIBSC Code 07/364). The traceability process is based on EN ISO17511.

# Stability and Value Assignment:

Stability and value assignment of Controls and Calibration Verification Materials was previously reviewed under k121237. Control materials have target concentrations of 25, 1000, and $1 5 0 0 \mathrm { I U / L }$ . Calibration Verification Materials have target concentrations of 3, 1000, and $2 0 0 0 \mathrm { I U / L }$ .

# d. Detection limit:

The Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantitation (LoQ) were determined in accordance with CLSI document EP17-A2. The LoB study was performed by measuring 195 replicates of one blank lithium heparin plasma pool and 144 replicates of one blank lithium heparin whole blood sample pool over five days with 2 reagent lots. The LoD study was performed by measuring 192 replicates of 4 low concentration lithium heparin plasma samples and 182 replicates of 6 low concentration lithium heparin whole blood samples over 5 days with 2

reagent lots. The LoQ study was performed by measuring 155 replicates of 4 low concentration lithium heparin plasma samples and 92 replicates of 6 low concentration lithium heparin whole blood samples over 6 days with 2 reagent lots. The results demonstrated $\mathrm { L o B } < \mathrm { L o D } \leq \mathrm { L o Q } < 5 . 0 \mathrm { I U } / \mathrm { L }$ . Recovery at the claimed lower assay limit of $5 \mathrm { I U / L }$ is shown above in section M.1.b. and summarized below:

<table><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Bias</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparinized Plasma</td><td rowspan=1 colspan=1>-0.2 to -1.2 IU/L</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparinized Whole Blood</td><td rowspan=1 colspan=1>0.3 to 1.1 IU/L</td></tr></table>

e. Analytical specificity:

Interference:

Following CLSI guideline EP07-A2, potential exogenous and endogenous interferents were spiked into both lithium heparinized whole blood and lithium heparinized plasma with various hCG concentrations including hCG concentrations near decision limits. Measured hCG concentrations in the presence of interferent were compared to measured hCG concentrations in control samples without interferent, and recoveries were determined. The following compounds were tested at the concentrations shown below. No interference was observed. All recoveries in the presence of the compounds shown below were within $+ / - 1 0 \%$ (the criterion defined by the Sponsor).

<table><tr><td colspan="1" rowspan="1">Substance</td><td colspan="1" rowspan="1">Test Concentration</td></tr><tr><td colspan="1" rowspan="1">Acetaminophen</td><td colspan="1" rowspan="1">1660 uM</td></tr><tr><td colspan="1" rowspan="1">Acetyl Salicylic Acid</td><td colspan="1" rowspan="1">3620 uM</td></tr><tr><td colspan="1" rowspan="1">Allopurinol</td><td colspan="1" rowspan="1">294 uM</td></tr><tr><td colspan="1" rowspan="1">Ampicillin</td><td colspan="1" rowspan="1">152 uM</td></tr><tr><td colspan="1" rowspan="1">Ascorbic Acid</td><td colspan="1" rowspan="1">342 uM</td></tr><tr><td colspan="1" rowspan="1">Atenolol</td><td colspan="1" rowspan="1">37.6 uM</td></tr><tr><td colspan="1" rowspan="1">Atropine</td><td colspan="1" rowspan="1">20 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">308 uM</td></tr><tr><td colspan="1" rowspan="1">Captopril</td><td colspan="1" rowspan="1">23 uM</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">155 uM</td></tr><tr><td colspan="1" rowspan="1">Diclofenac</td><td colspan="1" rowspan="1">169 uM</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">6.53 uM</td></tr><tr><td colspan="1" rowspan="1">Dopamine</td><td colspan="1" rowspan="1">5.87 uM</td></tr><tr><td colspan="1" rowspan="1">Enalaprilat</td><td colspan="1" rowspan="1">0.86 uM</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">81.6 uM</td></tr><tr><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">181 uM</td></tr><tr><td colspan="1" rowspan="1">Gentisic Acid</td><td colspan="1" rowspan="1">117 uM</td></tr><tr><td colspan="1" rowspan="1">1buprofen</td><td colspan="1" rowspan="1">2425 uM</td></tr><tr><td colspan="1" rowspan="1">lsosorbide dinitrate</td><td colspan="1" rowspan="1">636 uM</td></tr><tr><td colspan="1" rowspan="1">Methyldopa</td><td colspan="1" rowspan="1">71 uM</td></tr><tr><td colspan="1" rowspan="1">Nicotine</td><td colspan="1" rowspan="1">6.2 uM</td></tr><tr><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">1156 uM</td></tr><tr><td colspan="1" rowspan="1">Phenytoin</td><td colspan="1" rowspan="1">198 uM</td></tr><tr><td colspan="1" rowspan="1">Propanolol</td><td colspan="1" rowspan="1">7.71 uM</td></tr><tr><td colspan="1" rowspan="1">Salicylic acid</td><td colspan="1" rowspan="1">4340 uM</td></tr><tr><td colspan="1" rowspan="1">Sodium Heparin</td><td colspan="1" rowspan="1">90 U/mL</td></tr><tr><td colspan="1" rowspan="1">Theophylline</td><td colspan="1" rowspan="1">222 uM</td></tr><tr><td colspan="1" rowspan="1">Verapamil</td><td colspan="1" rowspan="1">4.4 uM</td></tr><tr><td colspan="1" rowspan="1">Warfarin</td><td colspan="1" rowspan="1">65.2 uM</td></tr><tr><td colspan="1" rowspan="1">Albumin</td><td colspan="1" rowspan="1">60 g/L</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">342 uM</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">13 mM</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">2 g/L</td></tr><tr><td colspan="1" rowspan="1">Triglyceride</td><td colspan="1" rowspan="1">37 mM</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">1.4 mM</td></tr></table>

# Specificity:

Assay specificity was determined by testing hCG spiked lithium heparinized whole blood and heparinized plasma samples in the presence of LH $( 4 5 0 \mathrm { I U / L } )$ , FSH (300 IU/L) , and TSH $( 1 0 0 \mathrm { m U } / \mathrm { L } )$ , and comparing test results to hCG samples in the absence of these additional hormones. Recoveries were all within $+ / - 1 0 \%$ (criteria defined by the Sponsor).

# Hematocrit (HCT):

The effect of different hematocrit levels was evaluated using hCG levels in whole blood samples $( 2 0 { - } 3 0 \mathrm { I U / L }$ and $1 2 0 0 { - } 1 5 0 0 \mathrm { I U / L } )$ with hematocrit levels falling in one of four bins: Zero (plasma), Low $( 2 5 \% - 3 5 \% )$ , Nominal $( 3 6 \% - 4 3 \% )$ , and High $( 4 4 \% - 5 1 \% )$ . The labeling indicates that imprecision (CV) and bias exceeding $10 \%$ have been observed in samples with $\mathrm { H C T } > 5 0 \% \mathrm { P C V }$ (packed cell volume).

f. Assay cut-off:

See detection limit above (M.1.d.).

# 2. Comparison studies:

# a. Method comparison with predicate device:

The method comparison study was done in accordance with the CLSI guideline EP09-A2. The measurements were obtained at four external POC sites, where whole blood samples were collected and immediately tested in duplicate with the candidate device. The collection tubes were then transferred to the hospital laboratory. The plasma portion was separated from the red cells and the plasma portion of each sample was tested in duplicate with both the candidate and the predicate devices. Testing was performed by 6-8 operators at each POC site. Each sample was tested with a minimum of two lots of i-STAT Total $\beta$ -hCG cartridges and six i-STAT 1 Analyzers were used at each POC site.

The analyses of the first measurements of the whole blood (candidate device), plasma (candidate device) vs plasma (predicate) from all sites are shown below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>i-STAT (Whole Blood) vs.ARCHITECT (Fresh Plasma)</td><td rowspan=1 colspan=1>i-STAT (Fresh Plasma) vs.ARCHITECT (Fresh Plasma)</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>134</td><td rowspan=1 colspan=1>134</td></tr><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>0.95 (0.92 to 0.97)</td><td rowspan=1 colspan=1>1.02(1.00 to1.04)</td></tr><tr><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>2.39 (1.14 to 3.64)</td><td rowspan=1 colspan=1>-0.22 (-1.17 to0.73)</td></tr><tr><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>0.99 (0.98 to 0.99)</td><td rowspan=1 colspan=1>0.99 (0.98 to1.00)</td></tr></table>

# b. Matrix comparison:

The matrix comparison study was done in accordance with the CLSI guideline EP09- A2. Forty samples spanning the measurement range of the i-STAT Total $\beta \mathrm { . }$ -hCG test were prepared from 40 donor samples by spiking with a stock solution containing commercially available hCG antigen. Results of each sample type listed below were analyzed against the control (Li-heparin plasma), as shown below.

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Na-HeparinWhole Blood</td><td rowspan=1 colspan=1>Li-HeparinWhole Blood</td><td rowspan=1 colspan=1>Na-HeparinPlasma</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>40</td></tr><tr><td rowspan=1 colspan=1>Deming Slope(95% CI)</td><td rowspan=1 colspan=1>0.94 (0.91  0.98)</td><td rowspan=1 colspan=1>0.98 (0.95 - 1.01)</td><td rowspan=1 colspan=1>0.98 (0.95 - 1.00)</td></tr><tr><td rowspan=1 colspan=1>Deming Intercept(95% CI)</td><td rowspan=1 colspan=1>0.5 (0.3 - 0.6)</td><td rowspan=1 colspan=1>0.5 (0.2 - 0.7)</td><td rowspan=1 colspan=1>-0.5 (-1.9 - 0.8)</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The reference range study was performed according to CLSI Guideline C28-A3c. Human plasma and whole blood samples from apparently healthy non-pregnant women were tested to determine the reference range for the i-STAT Total $\beta$ -hCG test. The results are listed below:

<table><tr><td rowspan=1 colspan=1>ReferencePopulation age(years)</td><td rowspan=1 colspan=1>NSubjects</td><td rowspan=1 colspan=1>NWhole bloodresults</td><td rowspan=1 colspan=1>N Plasmaresults</td><td rowspan=1 colspan=1>Median(IU/L)</td><td rowspan=1 colspan=1>Range(IU/L)</td><td rowspan=1 colspan=1>95th Percentile(IU/L),[95% CI]</td></tr><tr><td rowspan=1 colspan=1>≥ 18 and &lt; 40</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0-3.9</td><td rowspan=1 colspan=1>0.7 [0.3, 1.6]</td></tr><tr><td rowspan=1 colspan=1>≥ 40</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0 - 9.6</td><td rowspan=1 colspan=1>4.5 [4.0 , 5.4]</td></tr><tr><td rowspan=1 colspan=1>≥ 40, pre-menopausal</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0-2.5</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>≥ 40, post-menopausal</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0 - 9.6</td><td rowspan=1 colspan=1></td></tr></table>

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.